SUMMARY
Several million genetically altered mice are used worldwide each year for research, toxicity testing, or simply to create
or sustain mutant models. In fact, as our understanding of the genetic differences between mice and men improves,
so does the drive to create mouse models of human disease and toxicity. However, while some models have proven
to be useful and confer tangible benefits in terms of clinical management of disease, many others add little value
to clinical medicine or human safety emphasising the need for a thorough investigation of the actual or future value
of such models to human medicine.
KEY WORDS
disease; genetically altered; mouse; mutant; welfare
REFERENCES
Ablamunits V, Elias D, Reshef T, Cohen IR: Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 11:73-81,
1998.
Akeson EC, Lambert JP, Narayanswami S, Gardiner K, Bechtel LJ, Davisson MT: Ts65Dn - localization of the translocation breakpoint and trisomic gene content in
a mouse model for Down syndrome. Cytogenet Cell Genet 93:270-276, 2001.
Ameen N, Alexis J, Salas P: Cellular localisation of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. Histochem Cell Biol
114:69-75, 2000.
Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in
mice. Nature, London 406:641-645, 2000.
Attardi LD, Jacks T: The role of p53 in tumour suppression: lessons from mouse models. Cell Molec Life Sci 55:48-63, 1999.
Ayash-Rashkovsky M, Bentwich Z, Arditti F, Friedman S, Reisner Y, Borkow G: A novel small animal model for HIV-1 infection Faseb J 19:1149-1151, 2005.
Bacchus C, Sterz H, Buselmaier W, Sahai S, Winking H: Genesis and systematization of cardiovascular anomalies and analysis of skeletal malformations in murine
trisomy 16 and 19: Two animal models for human trisomies. Hum Genet 77:12-22, 1987.
Boot HJ, Kasteel DTJ, Buisman A-M, Kimman TG: Excretion of wild-type and vaccine-derived poliovirus in the faeces of poliovirus receptor-transgenic mice. J
Virol 77:6541-6545, 2003.
Chang LJ, Zhang C: Infection and replication of tat-minus human immunodeficiency viruses: genetic analyses of LTR and tat GAs in primary and long-term human
lymphoid cells. Virol 211:157-169, 1995.
Cox DR, Palmiter RD: Assignment of the mouse metallothionein-1 gene to chromosome-8: Implications for human Menkes disease. Clin Res 30:A117-A117,
1982.
Cryan JF, Mombereau C: In search of a depressed mouse: utility of models for studying depression-related behaviour in genetically modified mice. Molec
Psychiarty 9:326-357, 2004.
Daingain J, Vrbova G: Muscle development in mdx GA mice. Muscle & Nerve 7:700-704, 1984.
Dalke C, Graw J: Mouse mutants as models for congenital retinal disorders. Exp Eye Res 81:503-512, 2005.
Dragunsky E, Nomura T, Karpinski K, Furesz J, Wood DJ, Perivikov Y, Abe S, Kurata T, Vanloocke O, Karganova G, Taffs R, Heath A, Ivshina A, Levenbook:
Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: Validation by a WHO collaborative study. Bulletin of
the World Health Organisation 81:251-262, 2003.
ElAmraoui A, Sahly I, Picaud S, Sahel J, Abitbol M, Petit C: Human Usher 1B mouse shaker-1: The retinal phenotype discrepancy explained by the presence/absence
of myosin VIIA in the photoreceptor cells. Hum Mol Genet 5:1171-1178, 1996.
Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR: Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and
downregulates autoimmunity to various beta-cell antigens. Diabetes 46:758-764, 1997.
Epstein CJ, Cox DR, Epstein LB: Mouse trisomy 16: An animal model of human trisomy 21 (Down syndrome). Annal New York Acad Sci 450:157-168, 1985.
Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD: Morpholino oligomer-mediated exon skipping averts the
onset of dystrophic pathology in the mdx mouse. Mol Ther 15:1587-1592, 2007.
Gardner KL, Kearney JA, Edwards JD, Rafael-Fortney JA: Restoration of all dystrophin protein interactions by functional domains in trans does not rescue
dystrophy. Gene Therapy 13:744-751, 2006.
Gibson F, Walsh J, Mburu P, Varela A, Brown KA, Antonio M, Beisel KW, Steel KP, Brown SD: A type VII myosin encoded by the mouse deafness gene shaker-1.
Nature, London 374:62-64, 1995.
Gotz J, Chen F, van-Dorpe J, Nitsch RM: Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529-534, 2001.
Greaves DR, Fraser P, Vidal MA, Hedges M, Ropers D, Luzzatto L, Grosveld F: A transgenic mouse model of sickle cell disorder. Nature, London 11:183-185,
1990.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000.
Hanna J, Wernig M, Markoulaki S, Sun C-W, Meissner A, Cassady JP, Beard C, Brambrink T, Wu L-C, Townes TM, Jaenisch R: Treatment of sickle cell anemia mouse
model with iPS cells generated from autologous skin. Science 318:1920-1923, 2007.
Hiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren P-O, Magnuson MA: Sulfonylurea
teceptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem
277:37176-37183, 2002.
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada C-M, Eckman
C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-type phenotype in transgenic mice carrying both GA mutant amyloid precursor protein and presenelin 1
transgenes. Nature Medicine 4:97-100, 1998.
Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC:
Developmental abnormalities and age-related neurodegeneration in a mouse model ofDownsyndrome. Proc Natl Acad Sci USA 93:13333-13338, 1996.
Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm A-C: Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of
estrogen. Neurobiology of Aging 25:873-884, 2004.
International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature London 409:860-921, 2001.
Jacobs GH, Neitz J, Deegan JF: Retinal receptors in rodents maximally sensitive to ultraviolet light. Nature London 353:655-656, 1991.
Jacobson-Kram D, Sistare FD, Jacobs AC: Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol 32:suppl. 1, 49-52, 2004.
Jenkins ES, Combes RD: The welfare problems associated with using transgenic mice to bioassay for bovine spongiform encephalopathy. Anim. Welfare 8:421-431,
1999.
Kanezaki Y, Obata T, Matsushima R, Minami A, Yuasa T, Kishi K, Bando Y, Uehara H, Izumi K, Mitani T, Matsumoto M, Takeshita Y, Nakaya Y, Matsumoto T, Ebina Y:
KATP channel knockout mice crossbred with transgenic mice expressing a dominant negative form of human insulin receptor have glucose intolerance but not
diabetes. Endo J 51:133-144, 2004.
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis.
Science, New York 245:1073-1080, 1989.
Kroese ED, van Steeg H, van Oostrom CT, Dortant PM, Wester P, van Kranen HJ, de Aries A, van Kreijl CF: Use of E-pim transgenic mice for short-term in
vivo carcinogenicity testing: Iymphoma induction by benzo[a]pyrene but not TPA. Carcinogenesis 19:975-908, 1997.
Kunzelmann K, Schreiber R, Konig J, Mall M: Ion transport induced by proteinase-activated receptors (PAR2) in colon and airways. Cell Biochem Biophys
36:209-214, 2002.
Lundkvist J, Zhu S, Hansson EM, Schweinhardt P, Qing M, Beatus P, Dannaeus K, Karlstrom H, Johansson CB, Viitanen M, Rozell B, Spenger C, Mohammed A, Kalimo H,
Lendahl U: Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis 41:13-22, 2004.
MacDonald JS: Human Carcinogenic Risk Evaluation, Part IV: Assessment of human risk of cancer from chemical exposure using a global weight-of-evidence
approach. Toxicol Sci 82:3-8, 2004.
MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, Swaroop A, Sowden JC, Ali RR: Retinal repair by transplantation of photoreceptor
precursors. Nature 444:203-207, 2006.
Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC: Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med
10:487-493, 2004.
Manci EA, Hilliery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS: Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell
disease. Blood 107:1651-1658, 2006.
Mansour SL, Thomas KR, Capecchi MR: Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting
mutations to non-selectable genes. Nature 336:348-352, 1988.
Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G: Infection by proxy: The role of chimeric mice in HBV
and HCV research. Morphological and biochemical characterization of a human liver in a uPASCID mouse chimera. Hepatol 41:847-856, 2005.
Mouse Genome Sequencing Consortium: Initial sequencing and comparative analysis of the mouse genome. Nature, London 420:520-562, 2002.
O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, Sesay A, Modino S, Vanes L, Hernandez D, Linehan JM, Sharpe PT, Brandner S, Bliss TVP,
Henderson DJ, Nizetic D et al.: An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309:2033-2037, 2005.
Paszty C, Brion CM, Manci E, Witowska HE, Stevens ME, Mohandas N, Rubin EM: Transgenic knockout mice with exclusively human sickle haemoglobin and sickle cell
disease. Science, New York 278:876-878, 1997.
Rozmahel E, Gyomorey K, Plyte S, Nguyen V, Wilschanski M, Durie P, Bear CE, Tsui LC: Incomplete rescue of cystic fibrosis transmembrane conductance regulator
deficient mice by the human CFTR cDNA. Hum Mol Genet. 6:1153-1162, 1997.
Satokata I, Maas R: Msx-1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nature Genetics 6:348-356, 1994.
Shichor T, Crawford M, Engelhardt T, Bell G, Bell D, Carmichael FJL, Kim PCW: HRC 101 improves survival during hypoxia in SAD mice. Canadian Journal of
Anesthesia 54:44491, 2007.
Sung C-H, Makino C, Baylor D, Nathans J: A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is
defective in localization to the photoreceptor outer segment. J Neurosci 14:5818-5833, 1994.
Trudel M, Saadane N, Garel MC, Bardakdjian-Michau J, Blouquit Y, Guerquin-Kern JL, Rouyer-Fessard P, Vidaud D, Pachnis A, Romeo PH, Beuzard Y, Costantini F:
Towards a transgenic mouse model of sickle cell disease: Hemoglobin SAD EMBO J 10:3157-3165, 1999.
Wahnschaffe U, Bitsch A, Kielhorn J, Mangelsdorf I: Mutagenicity testing with transgenic mice. Part I: Comparison with the mouse bone marrow micronucleus test.
J Carcinogen 4:2005. doi:10.1186/1477-3163-4-3.
Wicker LS, Clark J, Fraser HI, Garner VES, Gonzalez-Munoz A, Healy B, Howlett S, Hunter K, Rainbow D, Rosa RL, Smink LJ, Todd JA, Peterson LB: Type 1 diabetes
genes and pathways shared by humans and NOD mice. Journal of Autoimmunity 25:29-33, 2005.
Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, Okamiya H, Suzuki H, Fukuda T, Sakamaki Y, Sunaga M, Nomura G, Hioki K, Wakana S, Nomura T, Hayashi
Y: Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in
control non-transgenic mice. Carcinogenesis 17:2455-2461, 1996.
|
CITED
0
|
